Amorfix Life Sciences Ltd.
http://www.amorfix.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amorfix Life Sciences Ltd.
Alzheimer’s Disease: Moving Toward The Era Of Diagnostic Certainty
With more than 13 million people in the US expected to have Alzheimer’s disease (AD) by 2050, an increasing number of companies are focused on developing reliable AD diagnostics designed to facilitate early detection and treatment. Although the field remains in its relative infancy, researchers are gaining greater diagnostic certainty through a combination of diagnostic approaches, and over the next decade, the AD diagnostics market is projected to reach a US market value of at least $1 billion to $3 billion per year.
Amorfix appoints Warren Whitehead CFO
Warren Whitehead
Medical Device Deals Update, August 2012
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
Deals Shaping The Medical Industry, July-August 2012
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Diagnostic Equipment & Supplies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice